Abstract
You have accessJournal of UrologyProstate Cancer: Localized: Ablative Therapy II (MP70)1 Apr 2020MP70-20 OUTCOMES OF SALVAGE CRYOABLATION FOR LOCALIZED RADIO-RECURRENT PROSTATE CANCER: A SINGLE SURGEON EXPERIENCE Achankeng Afiadata*, Paul Prillaman, and Robert Given Achankeng Afiadata*Achankeng Afiadata* More articles by this author , Paul PrillamanPaul Prillaman More articles by this author , and Robert GivenRobert Given More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000950.020AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Cryoablation is a well-known versatile treatment modality for localized prostate cancer with reasonable functional outcomes. It is readily used in the setting of radio-recurrent, localized disease as opposed to salvage prostatectomy owing to less associated morbidity. Literature on long-term outcomes of salvage cryoablation is sparse. We investigated the oncologic outcomes and complications of salvage cryoablation for localized, radio-recurrent prostate cancer. METHODS: Retrospective review of patients who underwent salvage cryoablation for radio-recurrent prostate cancer at our institution from 2003 to 2019. Included patients had biopsy-proven local recurrence, and negative metastatic workup. Preoperative data, follow-up, oncologic outcomes, and associated morbidity were obtained. RESULTS: Eighty-six patients had salvage cryoablation for localized, radio-recurrent prostate cancer at our institution during the 16-year period. Mean age (SD) of patients was 71 (8), with Caucasian males making up 59% of the population. Majority of patients had prior external beam radiotherapy (EBRT), 82.6%, with a mean pre-cryoablation PSA (SD) of 2.5 (0.9) ng/mL. Median (IQR) follow up was 55.2 (21-94.8) months. Forty-two patients had no evidence of disease (NED), 52% of patients with pre-PSA of <4 had NED compared to 44.4% for pre-PSA ≥4. Median (IQR) biochemical free survival was 64 (30-140) months; 75 (36-140) months for pre-PSA <4, and 48 (24-84) months for pre-PSA ≥4 (P=0.0735). Long-term associated morbidities included: incontinence (26.7%), urethral stricture/stenosis (24.7%), and fistula (3.5%). CONCLUSIONS: Earlier (PSA <4 ng/mL) salvage cryoablation for localized radio-recurrent prostate cancer portends better oncological outcomes. Counsel patients on high rate of long-term incontinence and urethral stricture/stenosis associated with treatment. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1063-e1063 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Achankeng Afiadata* More articles by this author Paul Prillaman More articles by this author Robert Given More articles by this author Expand All Advertisement PDF downloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have